Identification of TYMS and DTL as Candidate Biomarkers of Cervical Cancer as Determined by Integrated Bioinformatics Analysis

• Published in: 2023 IEEE 5th Eurasia Conference on Biomedical Engineering, Healthcare and Sustainability (ECBIOS) pp. 44 - 49
• Main Authors: Chou, Yi-Fan, Chou, Pei-Yu, Sheu, Ming-Jyh, Wang, Charles C.N.
• Format: Conference Proceeding
• Language: English
• Published: IEEE 02.06.2023
• Subjects: biomarkers; cervical cancer; co-expression; denticles protein homolog; hub genes; Thymidylate synthetase
• DOI: 10.1109/ECBIOS57802.2023.10218537

Cervical cancer leads to female deaths and is prevalent in younger individuals. However, the prognosis in women with recurrent/metastatic cervical cancer is still poor. Therefore, further efforts to identify molecular targets for cervical cancer treatment are required. Here, we were trying to identify hub genes correlated with cervical cancer in silico, which could be essential for predicting implications and facilitating the exploration of novel treatments. The GSE9750 dataset based on the Gene Expression Omnibus database was analyzed to find genes that are expressed differently in healthy people and patients with cervical cancer. Weighted gene co-expression network analysis was performed to create networks of free-scale gene co-expression to determine the clinical characteristics of the genes. In the result, five gene expression modules were extensively linked to cervical cancer, of which the expression status of 24 genes from the blue module was further evaluated. The expression of the thymidylate synthetase (TYMS) and denticles protein homolog (DTL) hub genes showed a correlation with disease-free survival. In summary, TYMS and DTL may regulate cervical cancer progression and serve as potential biomarkers to understand the treatment outcome of cervical cancer